Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation

Kai Yun Ooi a,b, Ian Pereira c, Himanshu Nagar d, Richard Simcock e, Matthew S. Katz f, Christopher C. Parker g, Colleen Lawton b, Hina Saeed h,*

a Royal Marsden NHS Foundation Trust, Sutton, UK
b Kuala Lumpur Hospital, Malaysia
c Queen’s University, Kingston, Ontario, Canada
d New York Presbyterian Hospital, New York, NY, USA
e Sussex Cancer Centre, Brighton and Sussex University Hospitals NHS Trust, Sussex, UK
f Radiation Oncology Associates, Lowell, MA, USA
g Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
h Medical College of Wisconsin, WI, USA

ARTICLE INFO

Keywords:
Prostate radiotherapy
Adjuvant radiation
Salvage radiation
Journal club

ABSTRACT

Background: Management of prostate cancer after surgery is controversial. Past studies on adjuvant radiotherapy (aRT) for higher-risk features have had conflicting results. Through the collaborative conversations of the global radiation oncology Twitter-based journal club (#RadOnc #JC), we explored this complex topic to share recent advances, better understand what the global radiation oncology community felt was important and inspire next steps.

Methods: We selected the recent publication of a landmark international randomized controlled trial (RCT) comparing immediate and salvage radiotherapy for prostate cancer, RADICALS-RT, for discussion over the weekend of January 16 to 17, 2021. Coordination included open access to the article and an asynchronous portion to decrease barriers to participation, cooperation of study authors (CP, MS) who participated to share deeper insights including a live hour, and curation of related resources and tweet content through a blog post and Wakelet journal club summary.

Discussion of Results: Our conversations created 2,370,104 impressions over 599 tweets with 51 participants spanning 11 countries and 5 continents. A quarter of the participants were from the US (13/51) followed by 10% from the UK (5/51). Clinical or Radiation Oncologists comprised 59% of active participants (16/27) with 62% (18/29) reporting giving aRT within the last 5 years. Discussion was interdisciplinary with three urologists (11%), three trainees (11%), and two physiotherapists (7%). Four months after the journal club its article Alt-score had increased by 7% (214 to 229). Thematic analysis of tweet content suggested participants wanted clarification on definitions of adjuvant (aRT) and salvage radiotherapy (sRT) including indications, timing, and decision-making tools including guidelines; more interdisciplinary and cross-sectoral collaboration including with patients for study design including survivorship and meaningful outcomes; more effective knowledge translation including faster clinical trials; and more data including mature results of current trials, particular high-risk features (Gleason Group 4+, pT4b+, and margin-positive disease), implications of newer technologies such as PSMA-PET and genomic classifiers, and better explanations for practice pattern variations including underutilization of radiotherapy. This was further explored in the context of relevant literature.

Conclusion: Together, this global collaborative review on the postoperative management of prostate cancer suggested a stronger signal for the uptake of early salvage radiation treatment with careful PSA monitoring, more sensitive PSA triggers, and expected access to radiotherapy. Questions still remain on potential exceptions and

Abbreviations: KO, Kai Yun Ooi; IP, Ian Pereira; RS, Richard Simcock; MSK, Matthew Katz; CP, Christopher C Parker; CL, Colleen Lawton; HS, Hina Saeed; MS, Matthew Sydes.
* Corresponding author.
E-mail address: hisaeed@mcw.edu (H. Saeed).

https://doi.org/10.1016/j.ctro.2021.07.003
Received 7 July 2021; Accepted 26 July 2021
Available online 6 August 2021
2405-6308/Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Prostate cancer is the second most common cancer and fifth leading cause of cancer death in men worldwide with 1,414,259 new cases and 375,304 deaths in 2020, and increasing [1]. Radical prostatectomy (RP) is a standard treatment for clinically localized prostate cancer, which may be followed by adjuvant (aRT) or salvage (sRT) radiotherapy for select patients [2,3]. However, optimal timing of post-operative radiotherapy is debatable. Is it better to offer radiotherapy before a PSA failure occurs, or to consider only after confirmed biochemical relapse?

Patients with locally advanced pT3 disease, a positive surgical margin of length >1 mm, or Gleason Grade Group (GG) of at least 4 have a higher risk for biochemical recurrence [4]. Previous randomised controlled trials (RCTs) by the Southwest Oncology Group (SWOG 8794), European Organization for Research and Treatment of Cancer (EORTC 22911), German Cancer Society (ARO 96-02/AUO AP 09/95) and Finnish Radiation Oncology Group showed improvements in biochemical control in the sRT group compared to observation. Overall survival and metastasis free survival benefits were observed in SWOG 8794, but not in the other trials [5-8]. Amidst these results, aRT for patients with adverse pathological features has declined [9]. Hence, results from further clinical trials comparing aRT and early sRT such as RADICALS-RT have been eagerly anticipated to determine the standard of care after RP.

Twitter-based journal clubs are feasible and acceptable for convening a diverse global audience of health care providers from multiple disciplines and other public stakeholders to discuss and increase the impact of new research [10]. Moreover, qualitative methods such as focused conversations are increasingly used to explore complex care health topics. As such, the results of RADICALS-RT, an international phase 3 RCT in prostate cancer comparing an immediate postoperative (adjuvant) radiotherapy (aRT) and early salvage postoperative radiotherapy (esRT) policy was chosen for a collaborative review in the Radiation Oncology Journal Club (#RadOnc #JC) [11].

Methodology

This Twitter #RadOnc #JC was held from 8AM (CST) on Saturday January 16, 2021 to 2 pm on Sunday January 17, 2021 in accordance with the usual protocol to encourage global diversity and facilitate inclusion [12]. The preparatory process included negotiating free access to the publication for the week of the chat [11]. A blog post provided a brief summary of the study’s relevance and structured discussion topics (T1, T2, T3…Tn) for gentle appraisal (Supplementary: Table 3) [13]. Public tweets including the hashtag #pccm for the prostate cancer community and infographics were sent periodically during the week before the chat. Select Twitter accounts for oncologists, surgeons, and patient advocates around the world were tagged to encourage balanced participation. The asynchronous portion started Saturday 8AM. The live hour occurred Sunday 1–2 PM. Moderation was by a resident (IP) and practicing physicians (MSK, RS, & HS). Lead discussants included the study’s first author (CP) and chief statistician (MS). One Twitter poll was conducted on the use of adjuvant radiotherapy (Supplementary: Table 4).

After the journal club a social media analytics platform customized for healthcare (Symplur Signals [14]) was used to describe participant demographics. We organized tweets into a transcript using the social media content organization platform Wakelet and organized through thematic analysis [15]. As a measure of short-term change in attention, dissemination, and impact of the article, the baseline Altmetric Attention Score was collected the week prior to the journal club on January 8, 2021 and on May 3, 2021 [16]. These results were used to guide a discussion on global practice implications and new lines of inquiry.

Results

The journal club had 51 active discussants over the weekend share almost 600 tweets, participating from 10 countries from 5 continents. The discussion had 2.3 million impressions on Twitter (Table 1). There were 27 active participants whose input moved the discussion on the postoperative management of prostate cancer forward. Most active participants were from the US (48%) followed by the UK (18.5%). Most were physicians (85.2%), specifically radiation oncologists (51.9%).

A Twitter poll showed 62.1% (18/29) of participants gave aRT to patients for at least pT3 disease or a positive margin over the last 5 years, 34.5% did not, and the remainder could not recall (Supplementary: Table 4).

Four months after the journal club, the Article Altmetric Score had increased from 214 to 229 (7%) (Table 1).

We identified four key themes based on what participants felt was important for the postoperative radiotherapy management of prostate cancer since RADICALS-RT was published (Fig. 1). These themes included:

1. Clarification on Definitions: guided by RADICALS-RT and longer-term results of pending trials, participants desired guidance on how aRT and sRT are defined. This included incorporation of newer definitions into guidelines and decision-making tools. It was understood that these aids should account for different practice environments including their resource constraints.

2. Increased Collaboration: including more patient-reported outcomes in future trials, participation of other disciplines and patients in study design and interpretation, and more survivorship studies and development of interventions for long-term sequelae.

3. More Effective Knowledge Translation: including more implementation of pragmatic trial designs for faster, more relevant integration into practice and newer techniques to improve accrual, assist with timely interpretation, and reduce bias.

4. Identification of Priority Areas for Further Study: to better guide real-world application of RADICALS-RT results. Some participants expressed confidence that current evidence suggested a new standard of care of an early salvage policy (esRT) that included features traditionally used for aRT (GG4+, pT3b+, and margin-positive disease). However, others were hesitant to adopt this definition of sRT due to the limited long-term follow-up and representativeness of recent trials for patients with higher-risk disease or different practice settings given varying local patient and provider preferences including referral patterns, resource incentives, and constraints. For example, postoperative referrals to radiation oncology, multidisciplinary assessment, and tumor board discussions were described as more limited in the US compared to the UK. Other areas of uncertainty included the role of systemic treatments, treatment of pelvic lymph nodes, and dose-escalation with ongoing trials mentioned.

Discussion

The #RadOnc #JC provided a collaborative review of the recent RADICALS-RT trial results on postoperative radiotherapy and further developed lines of inquiry.
Radiotherapy has a historical and ongoing variation in utilization. SWOG 8794 suggested improved metastasis-free and overall survival with aRT. During this time, the rates of aRT in the United States (USA) were low (9.9%) and unchanged from 2004 to 2011, due partly to skepticism of SWOG results and its trial design in the pre-PSA era and very slow accrual [17]. Patients treated at high-volume surgical facilities were less likely to receive aRT compared with low-volume facilities (7.8% vs 15.9%; adjusted odds ratio 0.58 [95% confidence interval, 0.50–0.65]; \( P < 0.0001 \)) and there was also less utilization according to race, lower income, and lower population density [17]. Similar patterns were noticed in Canada with 39% of appropriate patients being referred to radiation oncology for a discussion on aRT per guidelines and 20%...
receiving it [18]. Even for sRT where indications are stronger utilization was under 30% in Michigan, USA from 2012 to 2016 [19]. Although similar to the lower than clinically expected 33% of patients in SWOG 8794 (US/Canada) & EORTC 22911 (EU) in the observation arms who received sRT, it is much less than the 86% of patients in the Finn Prostate study (Finland) that received sRT (37/43). As such, this underutilization of radiotherapy is concerning.

Safety is a cornerstone of radiation oncology. Recently, radiation safety has received international attention with governments worldwide ratifying a World Health Organization (WHO) Global Action Plan on Patient Safety to mobilize resources, share knowledge, and facilitate coordination at all levels including a focus on health care institutions [20]. Standardization is widely recognized as an effective means to reduce errors and is used for global radiotherapy resource allocation. This does not mean textbook adherence to a single algorithm, but rather careful consideration of evidence-based standard options that may best fit patient, provider, and health system preferences and constraints. The journal club poll and analysis of content supported historical and ongoing variations in practice among oncologists worldwide with a possible majority (62%) preferring aRT for pT3+ or margin positive disease in the setting of an undetectable postop PSA. Further variation in the definitions for sRT included use in the setting of a detectable postop PSA, triggers for sRT, and the acceptable time period for salvage. For aRT, variations existed with indications, especially perceived utility for higher-risk disease (GG4+ or pT3b+) or patient populations with less access to early sRT. Workup (i.e. PSMA-PET, MRI, or Genomic Classifiers), treatment of pelvic nodal regions, and use of systemic agents also varied (Fig. 1). However, participants anticipated having these variations explained with the incorporation of RADICALS-RT and other pending trials into guidelines.

**Clinical guidelines may converge**

Clinical guidelines still vary. The European Society of Medical Oncology (ESMO) guideline states immediate postoperative radiotherapy after RP (aRT) is not routinely recommended [21]. This is supported by three RCTs (RADICALS-RT, RAVES and GETUG-AFU 17) [8,11,22]. On the contrary, the 2019 American Society for Radiation Oncology (ASTRO)/American Urological Association (AUA) guideline [23] emphasizes that patients with high risk pathologic features should be informed of the benefits of aRT because of improvements in biochemical recurrence free survival and the 2021 US National Comprehensive Cancer Network (NCCN) guidelines suggest evidence supports offering it in these populations [24]. This decision is based on SWOG 8794, EORTC 22911, and ARO 96-02 [5-7]. As evidence and its interpretation matures so should clinical guidance based on local clinical needs.

**Clarifications of previous trials**

PSA has long been used as a marker and endpoint in all stages of prostate cancer. Previous RCTs consistently showed improved long-term biochemical progression free survival (bPFS) with aRT (Table 2). Participants highlighted common confusions in interpretation of PSA based on when it was measured (after RP, aRT, or sRT) and its level. For example, patients on an observation policy after prostatectomy may still be eligible for sRT after PSA failure to potentially improve survival and chance of cure, if it is detected before distant progression, offered, and received. After aRT, patients no longer have this option. Unlike distant metastasis-free survival (DMFS) as a validated surrogate endpoint [25], bPFS has not been shown to be a surrogate for harder endpoints such as overall survival (OS).

Results of SWOG 8794 and EORTC 22,911 differed. While SWOG demonstrated improved 15-year distant-metastases free survival (DMFS) for aRT (46% vs. 38% for observation) and OS (47% vs. 37% for observation) [26], EORTC showed no difference in 10-year rate of distant metastases (10.1% for aRT; 11% for observation) or OS (80%) [6].

Unlike subsequent trials, SWOG & EORTC included patients with a detectable postoperative PSA. This is now considered ‘PSA persistence’ with a known worse prognosis. In SWOG slightly more patients with PSA persistence (PSA > 0.2 ng/mL) received radiotherapy classified as ‘adjuvant’ (36% vs 28% of patients in EORTC). For both trials, median PSA at time of salvage was higher than conventional triggers (0.75 ng/mL in SWOG; 1.7 ng/mL in EORTC) and overall rates of sRT at 10-years was low (33% or 70/211 in SWOG; 164/502 in EORTC). Although still debated by participants, benefits of aRT seen in SWOG may have been due to its definition of aRT and lack of timely sRT.

**Radicals-RT**

Radiotherapy and Androgen Deprivation In Combination After Local 

---

**Table 2**

| Clinical Trial | Inclusion Criteria | Arms | No. of patient | Median Follow up (Years) | Outcome | Toxicity |
|----------------|-------------------|------|----------------|--------------------------|---------|---------|
| SWOG 8794 1988-1997 | pT3 | aRT | 425 | >12 | aRT improved DMFS (HR 0.71, 95% CI 0.54, 0.94) OS (HR 0.72, 95% CI 0.55, 0.96) | No difference at 5 years |
| EORTC 22911 1992-2001 | pT2-3 | aRT | 1005 | 10.6 | aRT improved BPFS (HR 0.49, 95% CI 0.41–0.59) No difference in OS (HR 1.18, 95% CI 0.91–1.53) | Higher late toxicities in aRT, G3 ≤ 2% |
| ARO 96-02 1997-2004 | pT3-4 | aRT | 388 | 9.3 | G3 GU toxicities 1% in aRT |
| Finn Prostate group 2004-2012 | pT2 + positive margin or pT3a | aRT | 250 | 9 | aRT improved BPFS (0.30, 95% CI 0.16–0.54) Higher GI/GU/sexual function toxicities in ADT |
| RAVES 2009-2015 | pT3 | aRT Early Salvage RT (PSA ≥ 0.20) | 333 | 6.1 | Higher ≥ G2 GU toxicities in aRT |
| GETUG-AFU 17 2008-2016 | pT3 – 4 | aRT | 718 | aRT improved DMFS (HR 0.71, 95% CI 0.54, 0.94) OS (HR 0.72, 95% CI 0.55, 0.96) | No difference in EFS (HR 0.81, 95% CI 0.48–1.36) Higher GU toxicities, erectile dysfunction in aRT |

Gleason Score (GS), Extracapsular extension (ECE), Seminal vesicle invasion (SVI), Adjuvant radiotherapy (aRT), Salvage radiotherapy (sRT), Radical prostatectomy (RP), Wait and see (WS), Event free survival (EFS), Gastrointestinal (GI), Genitourinary (GU).
Clinical and Translational Radiation Oncology 31 (2021) 21–27

K. Yun Ooi et al.

Surgery (RADICALS-RT) was designed to address limitations of previous trials by comparing aRT and sRT with timely access to RT and carefully defined PSA inclusion and triggers for salvage. It was the largest RCT for the optimal timing of radiotherapy after RP for prostate cancer (n = 1396). RADICALS-RT enrolled patients with at least one risk factor (pathological T-stage 3 or 4, Gleason score of 7–10, positive margins, or preoperative PSA ≥ 10 ng/ml) between November 2007 and December 2016. Participants were assigned in a 1:1 ratio to adjuvant radiotherapy (aRT) or an observation policy with salvage radiotherapy (sRT) for PSA failure. In its recently reported results, at a median follow-up of 4.9 years there was no difference in bPFS (HR for aRT 1-10, 95% CI 0.81–1.49; p = 0.56). The definition of PSA failure was revised from that used in earlier trials to make a more appropriate comparison between arms. Freedom from non-protocol hormone therapy at 5 years was 93% with aRT versus 92% with sRT (HR 0.88, 95% CI 0.58–1.33; p = 0.53). Toxicity was more common with aRT. Most GI/GU events were of low severity. Grade 3–4 haematuria was 3% with aRT and < 1% with sRT during the first 2 years. Grade 3–4 urethral strictures were 6% with aRT and 4% with sRT (p = 0.020). The authors concluded an observation policy with early sRT for PSA failure was the current standard after RP.

Redefining PSA standards

RADICALS-RT was designed to test aRT against early sRT for PSA failure. In the previous trials, many patients in the observation arm did not receive timely salvage radiotherapy in the event of PSA failure. PSA failure after RP can be nuanced with various definitions cited in literature. The American Association of Urology (AAU) guidelines define biochemical recurrence as an initial PSA > 0.2 ng/mL confirmed by two consecutive readings [27–28]. RADICALS-RT used a more sensitive trigger for salvage radiotherapy: (a) two consecutive rises and PSA ≥ 0.1 ng/mL or (b) three consecutive rises even if final PSA was <0.1 ng/mL. RT was started within two months of randomization (aRT) or PSA failure (sRT). Journal club participants felt this was an improvement from previous trials.

Reclassifying postoperative risk

The majority of patients in RADICALS-RT were in a relatively favourable risk group. Gleason 3 + 4 disease was in 49%, 4 + 3 in 27%, and median PSA at diagnosis was 7.9 ng/mL (IQR 5.7–11.5 ng/mL). T-stage was pt2 in 24% and pt3a in 57%. PSA persistent patients were excluded. Strict PSA monitoring and salvage policies were followed. Most patients were also from the UK (82%) that has more concentrated geography than Ireland or Canada (over 3-times and almost 70-times respectively) and more universal healthcare than many other countries. Lack of access to PSA monitoring or early sRT in some populations may compromise the outcomes of a salvage policy. RADICALS-RT provided participants with reassurance that sRT is comparable to aRT for earlier endpoints with less toxicity, especially in certain populations.

Known features of poor outcomes post-prostatectomy were in a minority of studied patients. Similar to RAVES, median preoperative PSA in RADICALS-RT was < 10 ng/mL. While pre operative PSA was not reported in GETUG, similar to both GETUG and RAVES, a minority of patients had pt3b seminal vesicle involvement (18.7% or 261/1396), pt14 disease (9/1396), Gleason Score 8 + in 17% (235/1396), or lymph node involvement (62/1396) [11]. However, as part of the study protocol the ARTISTIC collaboration performed an aggregated data meta-analysis that suggested no difference in the effect of these variables [29]. This provided more reassurance of greater applicability, although some participants still preferred waiting for more mature results from all three trials before accepting early sRT as standard in these populations.

The journal club discussed other emerging factors to further categorize risk. With improved pathologic and surgical techniques this included the extent of microscopically positive margins. Some participants suggested robotic surgery may influence the incidence of positive margins. A retrospective review and analysis reported less frequent positive margins in robotic-assisted laparoscopic prostatectomy compared to conventional open RP (28.6% v 57.5%; P < 0.001) [30]. Other considerations were the impact of newer staging studies (e.g. MRI, PSMA-PET) or genomic classifiers to further refine post-prostatectomy risk and guide treatments.

Exploring radiotherapy details

During the journal club, participants debated factors other than timing that may influence postoperative radiotherapy outcomes, including optimal treatment volume, differing dose schedules, and using concurrent hormonal treatment.

Pelvic lymph node radiotherapy (PLNRT)

PLNRT remained contentious among participants. RADICALS-RT delivered aRT or sRT to the prostate bed. PLNRT could be added at the discretion of the treating oncologist, but was only used in 21 (3%) of 649 patients on sRT and 15 (7%) of 228 patients on aRT. In the intact prostate setting, a recent RCT from India (POP-RT) compared hypofractionated RT to the prostate (68 Gy/25#) to the same RT to the prostate with conventional RT to the pelvic nodes (50 Gy/25#) using image-guided IMRT. It accrued 224 patients from 2011 to 2017. Addition of PLNRT resulted in higher GU toxicity (17.7% v 7.5%, p = 0.03), but this was not reflected in patient-reported quality of life (QOL) [31]. GI toxicity was similar (6.5% v 3.8%, p = 0.39). Postoperative toxicities are expected to be higher. The older RTOG 0534 SPPORT trial that opened in 2007 showed higher acute grade 2 GI and bone marrow toxicities (p < 0.001) with PLNRT, with no increase Grade 3 GI/GU early or significant late toxicities [32]. Of note, unlike POP-RT, SPPORT allowed 3DCRT and port-film image guidance with PTV expansions from 6 to 15 mm. Results from both suggested improved outcomes, with POP-RT showing a 5-year bRFS of 95% with the addition of PLNRT (95% CI, 88.4 to 97.9) versus 81.2% (95% CI, 71.6 to 87.8) to the prostate alone (unadjusted HR of 0.23, 95% CI 0.10 to 0.52; P < 0.0001). Interestingly, addition of PLNRT also showed higher 5-year DFS (89.5% v 77.2%; HR 0.40; 95% CI, 0.22 to 0.73; P = 0.002) and DMFS (95.9% v 89.2%; HR 0.35; 95% CI, 0.15 to 0.82; P = 0.01). OS did not differ (92.5% v 90.8%, P = 0.83) [31]. Although PLNRT results are still maturing, they suggest tradeoffs that require further exploration.

Hypofractionation

Hypofractionation was discussed in the context of risk-reduction amidst the COVID-19 pandemic and stressed resource constraints. A retrospective cohort study of 461 US patients compared hypofractionation radiotherapy and conventional fractionation (median dose 65 Gy at 2.5 Gy per fraction vs median dose 66 Gy at 1.8–2.0 Gy per fraction) [33]. This study suggested no difference in bPFS on multivariate analysis (HR 0.64, 95% CI 0.41–1.02, P = 0.059), or GI toxicity. There was increased late >= 3 GU toxicity at 6 years with hypofractionation (11% v 4%, p=0.0081). Participants anticipated higher quality evidence from RADICALS-RT and other studies when available.

Hormone treatment (HT)

In RADICALS-RT, hormone treatment was under the discretion of the treating clinician or dictated by enrollment in RADICALS-HD where patients were allocated to HT for 0, 6, or 24 months. Three other RCTs (RTOG 9601, GETUG-AFU 16 and RTOG 0534) investigated HT with sRT. At a median follow-up of 13 years, RTOG 9601 showed improved OS with 24 months of bicalutamide versus placebo (HR for death 0.77, 95% CI 0.59 to 0.99; P = 0.04). There were also reductions in cumulative distant metastases (14.5% with bicalutamide v 23.0% with placebo, P = 0.005). Conversely, GETUG-AFU 16 showed no difference in 10-year OS, although this was with short-course androgen deprivation treatment with 6 months of goserelin (86%, 95% CI 81–89 v 85%, 95% CI 80–89 with RT alone, HR 0.93, 0.63–1.39; p = 0.73) [22]. Interim analysis of RTOG 0534 at median follow up 6.4 years reported a difference in freedom from progression (FFP) between salvage with prostate bed RT...
Tradeoffs

Expectedly, toxicity is more common with aRT. In RADICALS-RT, most RTOG toxicity was ≤ grade 2. Grade 3 + GU/GI toxicity was < 5% and < 1% respectively. In the first two years post-randomization, grade 3 + urothelial stricture was more common with aRT (39 [6%] v 30 [4%]). Patient-reported quality of life (QoL) was measured using validated Patient-Reported Outcome Measures (PROMs) suggested more GU/GI symptoms with aRT at one-year post-randomisation (p = 0.0023). This difference resolved at 5-years (p = 0.073, p = 0.084), but compliance with PROMs was less complete at later timepoints. This increased toxicity with aRT was consistent with global QoL measures in SWOG 8794 that showed statistically significant increases in GU PROMs at 6 weeks and 2 years, but not at 5 years [5]. Sexual function was measured in RADICALS-RT and reporting is pending. The highest grade 3 + adverse event in the Finn Prostate study group was erectile dysfunction with aRT (37% v 28%) and is expected to be similar [34]. Although RADICALS-RT did not perfectly fit all post-prostatectomy patient populations perfectly, and more mature outcomes are still pending, participants discussed the cost of this uncertainty in outcomes against the tradeoff of the known toxicity with aRT when deciding to accept sRT as a standard.

Pragmatism in learning systems

Participants largely praised the RADICALS-RT trial team for their adaptive methodologies. RADICALS-RT opened in 2007 with disease-specific survival (DSS) as its primary endpoint. Shortly after, early results of SWOG 8794 suggested improved survival in post-prostatectomy patients due to advances such as the use of Docetaxel with the recognition of castrate-resistant disease and competing causes of death. Expected events decreased and to prevent delaying timely results beyond 10 years for the same statistical power the primary endpoint was changed to DMFS. Early results of RAVES and GETUG-17 then suggested a lower number of primary events doubling the expected necessary follow-up. Implementing collaborative practices including effective inter-trial communication, trial coordinators created the ARTISTIC follow-up. Implementing collaborative practices including effective inter-trial communication, trial coordinators created the ARTISTIC follow-up. Imple
[21] Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(9):1119–34.

[22] Sargs P, Chabaud S, Latorzeff I, Magne N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020;21(10):1341–52.

[23] Pisarski TM, Thompson IM, Valicenti RK, D’Amico AV, Selvarajah S. Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018. Pract Radiat Oncol 2019;9(4):208–13.

[24] Prostate Cancer (v2.2021). 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed May 27, 2021.

[25] Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, et al. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. Lancet Oncol 2021;22(3):402–10.

[26] Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181(3):956–62.

[27] Cookson MS, Ault G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177(2):540–5.

[28] Cornford P, Bellmunt J, Bolla M, Briere E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017;71(4):630–42.

[29] Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020;396(10260):1422–31.

[30] Hong H, Mel I, Taylor J, Wu Q, Reeves H. Effects of robotic-assisted laparoscopic prostatectomy on surgical pathology specimens. Diagn Pathol 2012;7:24.

[31] Murphy V, Maitre P, Kamran S, Panizghani G, Krishnamurty R, Bakshi G, et al. Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol 2021;39(11):1234–42.

[32] Pollack A, Karrison TG, Balogh AG, Low D, Bruner DW, Wefel JS, et al. Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTSG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys 2018;102(5):1605. https://doi.org/10.1016/j.ijrobp.2018.08.052.

[33] Tandberg DJ, Oyekunle T, Lee WR, Wu Y, Salama JK, Koontz BF. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. Int J Radiat Oncol Biol Phys 2018;101(2):396–405.

[34] Salonen AJ, Taari K, Ala-Omar M, Viitanen J, Lundstedt S, Tammela TLJ. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187(6):2074–81.